Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

AstraZeneca (AZN - Analyst Report) and partner Targacept, Inc. (TRGT - Snapshot Report) recently amended their existing agreement. As per the revised agreement, Targacept has the full rights to develop and commercialize alpha7 NNR modulators for any indication including cognitive disorders and schizophrenia. Before the amendment, AstraZeneca had an option to license any alpha7 NNR modulator targeting a cognitive disorder or schizophrenia.

AstraZeneca will also forgo its rights to TC-1734 (AZD3480, alpha4beta2 modulator).  TC-1734 is currently being evaluated in a phase IIb trial for the treatment of mild-to-moderate Alzheimer's disease.

Under the terms of the restructured agreement, AstraZeneca gains the development and commercialization rights to alpha4beta2 NNR modulators including AZD1446 for all indications. Before, AstraZeneca only had rights to alpha4beta2 NNR modulators for cognitive disorders and schizophrenia.

Recently, AstraZeneca was in the news when three patents protecting its cholesterol management drug, Crestor (rosuvastatin), were rendered invalid by the Federal Court of Australia.

Generic competition has adversely impacted AstraZeneca’s revenues over the past few quarters. This has put significant pressure on the company. Additionally, there is increasing uncertainty regarding Crestor due to the entry of generic versions of Pfizer’s (PFE - Analyst Report) Lipitor in Nov 2011.

The company’s much-hyped antiplatelet drug Brilinta’s performance has remained lukewarm. AstraZeneca is looking to combat the generic threat through deals and acquisitions and cost-cutting measures.

AstraZeneca carries a Zacks Rank #3 (Hold), while Targacept carries a Zacks Rank #5 (Strong Sell). Right now, Shire plc (SHPG - Analyst Report) looks more attractive in the pharma space with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%